Login / Signup

Associations of proton pump inhibitors with susceptibility to influenza, pneumonia, and COVID-19: Evidence from a large population-based cohort study.

Ruijie ZengYuying MaLijun ZhangDongling LuoRui JiangHuihuan WuZewei ZhuoQi YangJingwei LiFelix W LeungChongyang DuanWeihong ShaHao Chen
Published in: eLife (2024)
This work is supported by the National Natural Science Foundation of China (82171698, 82170561, 81300279, 81741067, 82100238), the Program for High-level Foreign Expert Introduction of China (G2022030047L), the Natural Science Foundation for Distinguished Young Scholars of Guangdong Province (2021B1515020003), the Guangdong Basic and Applied Basic Research Foundation (2022A1515012081), the Foreign Distinguished Teacher Program of Guangdong Science and Technology Department (KD0120220129), the Climbing Program of Introduced Talents and High-level Hospital Construction Project of Guangdong Provincial People's Hospital (DFJH201923, DFJH201803, KJ012019099, KJ012021143, KY012021183), and in part by VA Clinical Merit and ASGE clinical research funds (FWL).
Keyphrases
  • quality improvement
  • public health
  • healthcare
  • coronavirus disease
  • sars cov
  • acute care
  • adverse drug
  • clinical practice
  • acute respiratory distress syndrome
  • respiratory syndrome coronavirus